Search Results - "Calleja, José L."

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial by Villanueva, Càndid, Albillos, Agustín, Genescà, Joan, Garcia-Pagan, Joan C, Calleja, José L, Aracil, Carles, Bañares, Rafael, Morillas, Rosa M, Poca, María, Peñas, Beatriz, Augustin, Salvador, Abraldes, Juan G, Alvarado, Edilmar, Torres, Ferran, Bosch, Jaume

“…Clinical decompensation of cirrhosis is associated with poor prognosis. Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure…”
Get full text

Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis by Villanueva, Càndid, Albillos, Agustín, Genescà, Joan, Garcia-Pagan, Joan C., Brujats, Anna, Calleja, José L., Aracil, Carles, Bañares, Rafael, Morillas, Rosa M., Poca, María, Peñas, Beatriz, Augustin, Salvador, Abraldes, Juan G., Alvarado, Edilmar, Torres, Ferran, Bosch, Jaume

“…The prognosis of compensated cirrhosis is good until decompensation. In decompensated cirrhosis, bacterial infections (BIs) are common and increase the risk of…”
Get full text

Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C by Fernández, Inmaculada, Muñoz-Gómez, Raquel, Pascasio, Juan M, Baliellas, Carme, Polanco, Natalia, Esforzado, Nuria, Arias, Ana, Prieto, Martín, Castells, Lluis, Cuervas-Mons, Valentín, Hernández, Olga, Crespo, Javier, Calleja, José L, Forns, Xavier, Londoño, María-Carlota

“…Graphical abstract…”
Get full text

Spleen Stiffness: The “New Kid on the Block” in the Diagnosis of Clinical Significant Portal Hypertension by Llop, Elba, Calleja, José L.

Get full text

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology by Calleja, José L., Rivera‐Esteban, Jesús, Aller, Rocío, Hernández‐Conde, Marta, Abad, Javier, Pericàs, Juan M., Benito, Hugo G., Serra, Miguel A., Escudero, Amparo, Ampuero, Javier, Lucena, Ana, Sánchez, Yolanda, Arias‐Loste, María T., Iruzubieta, Paula, Romero‐Gómez, Manuel, Augustin, Salvador, Crespo, Javier

“…Background & Aims Non‐alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with…”
Get full text

Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study by Buti, María, Manzano, María L, Morillas, Rosa M, García-Retortillo, Montserrat, Martín, Leticia, Prieto, Martín, Gutiérrez, María L, Suárez, Emilio, Gómez Rubio, Mariano, López, Javier, Castillo, Pilar, Rodríguez, Manuel, Zozaya, José M, Simón, Miguel A, Morano, Luis E, Calleja, José L, Yébenes, María, Esteban, Rafael

“…Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of…”
Get full text

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection by Manns, Michael P, Bourlière, Marc, Benhamou, Yves, Pol, Stanislas, Bonacini, Maurizio, Trepo, Christian, Wright, David, Berg, Thomas, Calleja, José L, White, Peter W, Stern, Jerry O, Steinmann, Gerhard, Yong, Chan-Loi, Kukolj, George, Scherer, Joe, Boecher, Wulf O

“…Background & Aims BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in…”
Get full text

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin by Romero‐Gómez, Manuel, Diago, Moisés, Andrade, Raúl J., Calleja, José L., Salmerón, Javier, Fernández‐Rodríguez, Conrado M., Solà, Ricard, García‐Samaniego, Javier, Herrerías, Juan M., De la Mata, Manuel, Moreno‐Otero, Ricardo, Nuñez, Óscar, Olveira, Antonio, Durán, Santiago, Planas, Ramón

“…Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment…”
Get full text

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients by Hinrichsen, Holger, Benhamou, Yves, Wedemeyer, Heiner, Reiser, Markus, Sentjens, Roel E., Calleja, José L., Forns, Xavier, Erhardt, Andreas, Crönlein, Jens, Chaves, Ricardo L., Yong, Chan-Loi, Nehmiz, Gerhard, Steinmann, Gerhard G.

“…Background & Aims: Novel, potent, and well-tolerated hepatitis C virus (HCV) drugs are needed. BILN 2061 is a potent and specific inhibitor of HCV serine…”
Get full text

Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients by Suárez, Emilio, Buti, María, Rodríguez, Manuel, Prieto, Martín, Pascasio-Acevedo, Juan M, Casanovas, Teresa, Crespo, Javier, Tapiador, Juan Arenas Ruiz, Gómez-Rodríguez, Rafael, Figueruela, Blanca, Diago, Moisés, Morillas, Rosa M, Zozaya, José M, Calleja, José L, Casado, Marta, Molina, Esther, Fuentes, Javier, Simón, Miguel A

“…OBJECTIVEThe objective of this study was to determine the long-term clinical outcome and persistence of hepatitis B surface antigen (HBsAg) loss after…”
Get full text

Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study by Rodríguez-Nóvoa, Sonia, García-Samaniego, Javier, Prieto, Martín, Calleja, José L, Pascasio, Juan M, Delgado Blanco, Manuel, Crespo, Javier, Buti, María, Bonet Vidal, Maria L, Arenas Ruiz Tapiador, Juan, Fernández-Rodríguez, Conrado, Solá, Ricard, Fraga, Enrique, González Diéguez, Luisa, Núñez, Oscar, Praga, Manuel, del Pino-Montes, Javier, Romero-Gómez, Manuel, Morillas, Rosa, Diago, Moisés, Castro, Ángeles

“…BACKGROUND:Cases of renal tubular dysfunction have been reported in patients with hepatitis B and in patients with human immunodeficiency virus who are…”
Get full text

Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study by Hernández-Conde, Marta, Fernández-Carrillo, Carlos, Llop, Elba, Perelló, Christie, López-Gómez, Marta, Martínez-Porras, José L, Fernández-Puga, Natalia, Calleja, José L

“…AbstractIntroduction and aimsTo determine the prevalence of minimal hepatic encephalopathy (MHE) in patients with liver cirrhosis (LC) due to hepatitis C virus…”
Get full text

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis by Lepida, Antonia, Colombo, Massimo, Fernandez, Inmaculada, Abdurakhmanov, Djamal, Ferreira, Paulo Abrao, Strasser, Simone I, Urbanek, Petr, Mangia, Alessandra, Calleja, José L, Iraqi, Wafae, DeMasi, Ralph, Lonjon-Domanec, Isabelle, Moreno, Christophe, Wedemeyer, Heiner

“…Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and…”
Get full text

Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study by Hernández-Conde, Marta, Fernández-Carrillo, Carlos, Llop, Elba, Perelló, Christie, López-Gómez, Marta, Martínez-Porras, José L, Fernández-Puga, Natalia, Calleja, José L

“…AbstractIntroduction and aimsTo determine the prevalence of minimal hepatic encephalopathy(MHE) in patients with liver cirrhosis (LC) due to hepatitis C virus…”
Get full text

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study by Turnes, Juan, Rincón, Diego, Calleja, José L, Delgado, Manuel B, Rosales, José M, Andrade, Raúl J, Manzano, María L, Salmerón, Francisco J, López, María A, Calvo, Marta, Gómez, Judith, Molina, Esther, Frias, Yza Nubia, Gálvez-Fernández, Roque Miguel, Vallejo-Senra, Nicolau, París, Sara, Santos de Lamadrid, Regina, Olveira, Antonio

“…The emergence of highly tolerable, effective, and shorter duration direct-acting antivirals (DAAs) regimens offers the opportunity to simplify hepatitis C…”
Get more information

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study by Buti, María, Manzano, María L, Morillas, Rosa M, García-Retortillo, Montserrat, Martín, Leticia, Prieto, Martín, Gutiérrez, María L, Suárez, Emilio, Rubio, Mariano Gómez, López, Javier, Castillo, Pilar, Rodríguez, Manuel, Zozaya, José M, Simón, Miguel A, Morano, Luis E, Calleja, José L, Yébenes, María, Esteban, Rafael

“…[This corrects the article DOI: 10.1371/journal.pone.0184550.]…”
Get full text

Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata by Lanas, Angel, Carrera-Lasfuentes, Patricia, García-Rodríguez, Luis A., García, Santiago, Arroyo-Villarino, María Teresa, Ponce, Julio, Bujanda, Luis, Calleja, José L., Polo-Tomas, Mónica, Calvet, Xavier, Feu, Faust, Perez-Aisa, Angeles

“…AbstractObjective. To assess rates of further bleeding, surgery and mortality in patients hospitalized owing to peptic ulcer bleeding. Materials and methods…”
Get full text

PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C by Ampuero, Javier, Campo, José A. Del, Rojas, Lourdes, García-Lozano, José R, Solá, Ricard, Andrade, Raúl, Pons, José A, Navarro, José M, Calleja, José L, Buti, María, González-Escribano, María F, Forns, Xavier, Diago, Moisés, García-Samaniego, Javier, Romero-Gómez, Manuel, M.D., Ph.D

“…AbstractBackground. Hepatitis C virus (HCV) is associated with a higher prevalence of steatosis compared to the general population. Aim. Our aim was to assess…”
Get full text

Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial by Lanas, Angel, Polo-Tomas, Mónica, García-Rodríguez, Luis A., García, Santiago, Arroyo-Villarino, María Teresa, Ponce, Julio, Bujanda, Luis, Calleja, José L., Calvet, Xavier, Feu, Faust, Perez-Aisa, Angeles, Sung, Joseph J. Y.

“…Abstract Objective. To assess clinical outcomes in patients treated with proton pump inhibitors (PPIs) after endoscopic hemostasis in routine clinical care,…”
Get full text

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent by Forns, Xavier, Gordon, Stuart C, Zuckerman, Eli, Lawitz, Eric, Calleja, Jose L, Hofer, Harald, Gilbert, Christopher, Palcza, John, Howe, Anita Y.M, DiNubile, Mark J, Robertson, Michael N, Wahl, Janice, Barr, Eliav, Buti, Maria

“…Graphical abstract…”
Get full text